The new IL-1 family cytokine IL-33 is synthesized as a 30kD precursor. Like pro-IL-1β, human pro-IL-33 was reported to be cleaved by caspase-1 to generate a 18kD fragment, which is sufficient to activate signaling by the IL-33 receptor T1/ST2. However, the proposed caspase-1 cleavage site is poorly conserved between species. In addition, it is not clear whether caspase-1 cleavage of pro-IL-33 occurs in vivo, and whether, like for IL-1β, this cleavage is a prerequisite for IL-33 secretion and bioactivity. In this study, we further investigated caspase-1 cleavage of mouse and human pro-IL-33 and assessed potential bioactivity of the IL-33 precursor. We observed generation of a 20 kD IL-33 fragment in cell lysates, which was enhanced by incubation with caspase-1. However, in vitro assays on mouse and human pro-IL-33 indicated that IL-33 is not a direct substrate for this enzyme. Consistently, caspase-1 activation in THP-1 cells induced cleavage of pro-IL-1β, but not of pro-IL-33, and activated THP-1 cells released full-length pro-IL-33 into culture supernatants. Finally, addition of fulllength pro-IL-33 induced T1/ST2 dependent IL-6 secretion in mast cells. However, we observed in situ processing of pro-IL-33 in mast cell cultures and it remains to be determined whether full-length pro-IL-33 itself indeed represents the bioactive species. In conclusion, our data indicate that pro-IL-33 is not a direct substrate for caspase-1. In addition, our results clearly show that caspase-1 cleavage is not required for pro-IL-33 secretion and bioactivity, highlighting major differences between IL-1β and IL-33.
IL-33, the most recently described cytokine of the IL-1 family, is synthesized as a 30kD precursor. Human pro-IL-33, like pro-IL-1β, was reported to be cleaved by caspase-1 in vitro to generate a 18kD fragment, termed mature IL-33, which is sufficient to activate signaling by the IL-33 receptor T1/ST2 (1) .
Caspase-1 is an endoproteinase, which specifically cleaves Asp -X bonds, where X typically refers to a small, often hydrophobic, residue (2) (3) (4) . Caspase-1 activity absolutely requires the presence of an Asp residue at position -1 of the cleavage site. Consistently replacement of Asp 116 by other amino acids, such as Ala, was previously demonstrated to prevent caspase-1 cleavage of pro-IL-1β (2). Recombinant mature IL-33 starts at Ser 112 for human IL-33, respectively at Ser 109 for mouse IL-33, neither of which correspond exactly to the position of a potential caspase-1 cleavage site. Indeed, the N-terminal moiety of human pro-IL-33 sequence contains a single Asp at position 110, and the N-terminal portion of mouse pro-IL-33 contains two Asp at positions 88 and 106 respectively. In fact, the region located between amino acids 80 and 110 of pro-IL-33 is rather poorly conserved between species (5). In particular, no Asp residues can be consistently found at an identical position across species to hint at the presence of a conserved caspase-1 cleavage site. So far, caspase-1 cleavage of pro-IL-33 has not been investigated in any species other than human.
Expression of endogenous IL-33 has been most extensively described in endothelial cells, where essentially nuclear, full-length 30 kD pro-IL-33 is detected (5-7). To date, only two studies have examined potential effects of caspase-1 activation on the processing and secretion of pro-IL-33 in living cells. In one study, stimulation of murine glial cultures with caspase-1 activators induced secretion of bioactive IL-33 into culture supernatants, but the size of the secreted protein was not assessed (8) . It is thus not clear whether caspase-1 cleavage of pro-IL-33 occurs in mouse cells. In a second study, Western blotting analysis revealed the presence of a 32 kD protein, as well as of minor 17 kD and 20 kD bands reacting with anti-IL-33 antibodies in the supernatants of THP-1 cells upon caspase-1 activation, suggesting secretion of full-length pro-IL-33, as well as of two potential cleavage products (9) . Although this last observation suggests that some pro-IL-33 may be secreted, it not known to which extent IL-33 secretion is dependent on caspase-1 cleavage. Finally, so far, all studies reporting T1/ST2-mediated effects of IL-33 were performed using the recombinant mature form of IL-33, while potential biological activity of the full-length precursor form has not been tested. It thus remains to be shown whether, like for IL-1β, caspase-1 cleavage is indeed required for IL-33 bioactivity.
In the present study, we thus further investigated caspase-1 cleavage of mouse and human pro-IL-33 in vitro and in cultured cells and assessed potential bioactivity of the IL-33 precursor. Cloning of mouse and human pro-IL-33 and pro-IL-1β expression vectors-An IMAGE EST clone containing the cDNA encoding the mouse full-length pro-IL-33 (GenBank accession n° BC003847) in the pCMV-Sport6 vector was used as expression vector for full-length mouse pro-IL-33 in 293T human embryonic kidney cells. Mutagenesis of Asp to Ala in mouse D88A and D106A pro-IL-33 mutants was performed using the Quickchange kit (Stratagene, La Jolla, CA) and appropriate primer pairs, according to the manufacturer's instructions. The cDNA corresponding to the full length human pro-IL-33 (GenBank accession n°AY905581) was amplified by RT-PCR using total RNA extracted from cultured rheumatoid arthritis synovial fibroblasts, with the following primers: forward 5'-cgggatccatgaagcctaaaatgaagtattc-3'; reverse 5'-gctctagactaagtttcagagagcttaaac-3' and cloned into the pCAGGSβ vector (10) for expression in 293T cells. For expression in THP-1 cells, human full length pro-IL-33 cDNA was cloned into the pWPI lentiviral vector (11) . Viral particles were produced in 293T cells using a standard protocol as described (12) . The cDNA corresponding to full length human pro-IL-1β (GenBank accession n°NM_000576) was amplified by RT-PCR using RNA extracted from PMA stimulated THP-1 cells, with the following primers: forward 5'-cgggatccggctgctctgggattctcttcag-3'; reverse 5'-gcctcgaggggtacagctctctttaggaag-3' and cloned into the pcDNA3.1+ vector (Invitrogen), for expression in 293T cells. The sequence of the entire coding region was verified before use for all constructs.
Experimental procedures

Materials-
Cell culture, transfection and lentiviral infection-Human embryonic kidney 293T cells were cultured in DMEM (4.5 g/l glucose) supplemented with L-glutamine, streptomycin, penicillin and 10% FCS at 37°C in a humidified atmosphere containing 5% CO 2 . For transfection, 293T cells were plated at a density of 100'000 cells/ml and transfected 24 hours after seeding with 1 µg/ml of pro-IL-33 or pro-IL-1β expression vectors, or empty vectors as a control, by calcium phosphate precipitation (13) . THP-1 cells were cultured in RPMI 1640 (4.5 g/l glucose) supplemented with Hepes 10 mM, sodium pyruvate 1 mM , 5x10-5 M β-mercaptoethanol, streptomycin, penicillin and 10% FCS. For viral infection, THP-1 cells were plated at a density of 250'000 cells/well and infected with freshly produced lentiviruses encoding either human IL-33 and GFP, or GFP alone as a control, using a double infection protocol (12) . P815 cells were cultured in DMEM (4.5 g/l glucose) supplemented with 6% FCS, HEPES 10mM, MEM non-essential amino acids 10mM, penicillin and streptomycin. Primary mouse bone marrow-derived mast cells (BMMC) were generated as described (14) from wild-type and T1/ST2 knockout BALB/c mice (15) and used after 10 weeks of culture.
In vitro protein synthesis-Wild-type, D88A and D106A mutant mouse pro-IL-33, as well as human pro-IL-33 and pro-IL-1β proteins were synthesized in vitro using the PURExpress TM In Vitro Protein Synthesis Kit (New England BioLabs Inc., Ipswich, MA). This kit consists in a cell-free coupled transcription/translation system reconstituted from purified components, and is thus essentially free of any contaminant proteases. To generate templates for the in vitro protein synthesis, the various cDNAs were amplified from the above described expression vectors using appropriate primers to insert a T7 promoter and an E. Coli ribosome entry site upstream of the gene specific sequence, according to the manufacturer's instructions. The sequence of all PCR products was verified before use. Protein synthesis was carried out using 250 ng of DNA template in a final volume of 25 µl. Reactions without cDNA were set up as negative controls.
In vitro caspase-1 assay-Transfected 293T cells were used 72 hours after transfection. Cells were lyzed in capsase assay buffer (Hepes 10 mM pH 7.5, CHAPS 0.1%, EDTA 2mM, glycerol 10%, DTT 10 mM) by brief sonication on ice and stored at -80° until use. Cell lysates (10 µl) were incubated for 6h at 37° without or with 2 units of recombinant active human caspase-1 (ALX-201-056, Alexis Corporation). In vitro synthetized proteins (0.7 µl) were incubated in 20 µl caspase buffer for 6h at 37° without or with 2 units of recombinant active human caspase-1. Reactions were stopped by addition of Laemmli buffer and samples were resolved on SDS-PAGE and analyzed by Western blotting.
Caspase-1 activation in THP-1 cellsLentivirally transduced THP-1 cells were stimulated for 3h with 0.5 µM PMA in complete RPMI and left to adhere overnight. Cells were then switched to Optimem medium (Invitrogen) and stimulated or not with 50 µg/ml LPS for 6h, as described previously (16) . Culture supernatants were removed and cell lysates prepared by freeze thawing after addition of fresh Optimem. Supernatant and cell lysate proteins were concentrated by methanol precipitation, resuspended in Laemmli buffer, resolved on SDS-PAGE and analyzed by Western blotting.
Western blotting-Samples were fractionated by SDS-PAGE and transferred to a Porablot membrane (Macherey-Nagel, Dueren, Germany). The membrane was blocked in TBS, 0.05%, Tween 20, containing 5% BSA or 5% blotto (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and immunoblotting was performed with one of the following antibodies, as indicated: biotinylated monoclonal anti-IL-33 antibody (Nessy-1, 1/1000, Alexis Corporation), biotinylated polyclonal anti-mIL-33 antibody (BAF3626, 1/2000, R&D Systems), polyclonal anti-hIL-33 antibody (AF3625, 1/1000, R&D Systems, Abingdon, UK), monoclonal anti-hIL-1β (MAB201, 1/1000, R&D Systems) or the D116 antibody specific for mature 17 kD h-IL-1β (1/1000, Cell Signaling Technology Inc., Danvers, MA). Immunoreactive bands were visualized by ECL (Amersham Pharmacia Biotech, Duebendorf, Switzerland), using appropriate HRP-coupled secondary reagents.
Immunofluorescence-Lentivirally transduced THP-1 cells were seeded in chamber slides, primed with 0.5 µM PMA and stimulated or not with 50 µg/ml LPS as described above. The cells were fixed (PBS, 4% paraformaldehyde, 10 minutes RT), permeabilized (PBS, 0,1% Triton X100, 10 minutes) and blocked (PBS, 1%BSA, 10% normal goat serum, 1 hour), before staining with a monoclonal anti-hIL-33 antibody (ALX-804-726, 1/100, Alexis Corporation) and detection with a texas red labeled anti-mouse IgG secondary antibody. To assess staining specificity, negative controls were performed in absence of the primary antibody. Slides were mounted using a DAPI containing mounting medium (Vector Laboratories, CA) and images were acquired on a LSM510 Meta confocal microscope (Carl Zeiss AG, Feldbach, Switzerland).
Purification of mouse pro-IL-33-293T were seeded in 10-cm petri dishes and transiently transfected with the mouse pro-IL-33 expression vector. Cells were harvested 72h after transfection in TNT (50 mM Tris pH 7.4, 150 mM NaCl, 0.5% Triton X-100), supplemented with a protease inhibitor cocktail (Roche Diagnostics AG, Rotkreuz, Switzerland) and lyzed by brief sonication on ice. Alternatively, transfected cells were used to prepare nuclear extracts following standard procedures (17) . Briefly, cells were lyzed in sucrose buffer on ice, nuclei were pelleted, resuspended in low salt buffer and lyzed by addition of high salt buffer. Mouse pro-IL-33 was affinity purified from TNT total cell extracts or from nuclear extracts using mouse sST2-Fc and the Seize X Protein G Immunoprecipitation Kit (Pierce, Rockford, IL) and eluted in 100-200 µl fractions using the acid (pH 2.8) elution buffer provided in the kit. Eluted fractions were neutralized using 5-10 µl Tris (1M, pH 9.5) and used for Western blotting (10 µl per lane) or, after addition of 0.1% BSA, stored at -80° until they were used to stimulate P815 cells or BMMC.
Bioactivity of purified and in vitro translated mouse pro-IL-33-Bioactivity of purified mouse pro-IL-33 or of in vitro synthesized wild-type, D88A and D106A mouse pro-IL-33 was assessed using P815 mastocytoma cells and BMMC (14) . P815 cells were plated in 96-well plates in 200µl of complete culture medium at a density of 20,000 cells per well and treated with the indicated concentrations of recombinant mIL-33 or with indicated dilutions of in vitro synthesis products for 24h before culture supernatants were harvested. To assess specificity of the observed effects, recombinant IL-33 or in vitro synthesized proteins were pre-incubated with sST2/Fc (50 µg/ml) for 15 minutes at 37° before addition to the cells. Alternatively, BMMC generated from wild-type or T1/ST2 knockout mice were incubated without or with purified pro-IL-33 (10 µl out of 200 µl total eluate), recombinant mIL-33 (1 ng/ml) or LPS (1 µg/ml) for 24h before culture supernatants were harvested. Levels of IL-6 in P815 and BMMC culture supernatants were assessed using an enzyme-linked immunosorbent assay (ELISA) DuoSet kit (R&D Systems).
Statistical analysisSignificance of differences was assessed by ANOVA. A difference between experimental groups was considered significant when the p value was less than 0.05.
RESULTS
Generation of a 20 kD fragment of IL-33.
Human pro-IL-33, like pro-IL-1β, was reported to be cleaved by caspase-1 in vitro to generate a 18kD C-terminal fragment (1). However, the proposed caspase-1 cleavage site is poorly conserved between species (5). We thus further investigated caspase-1 cleavage of mouse and human pro-IL-33. Mouse pro-IL-33 was overexpressed in 293T cells and total cell lysates were incubated with recombinant human active caspase-1 in vitro. Western blot analysis revealed the presence of a major band corresponding to the 30kD full length form of pro-IL-33, even after incubation with caspase-1 ( Figure 1A ). In addition, we detected a less intense band at 20 kD, the abundance of which was increased in presence of active caspase-1. No band corresponding to the size of rmIL-33 was detected either in absence or in presence of caspase-1. Similar results were obtained also upon incubation of the cell lysates with recombinant active mouse caspase-1 and using two different anti-mIL-33 antibodies (BAF3626 and Nessy) for detection ( Figure 1A and data not shown). In an attempt to identify which of the 2 Nterminal Asp residues might represent a potential caspase-1 cleavage site in mouse pro-IL-33, we generated two mutant forms of mouse pro-IL-33, D88A and D106A, in which either Asp 88 or Asp 106 was replaced by Ala. Surprisingly, neither of these two mutations interfered with the generation of the 20 kD band, which was detectable already in untreated cell lysates and slightly enhanced in presence of caspase-1 ( Figure 1B) .
Similarly, lysates of 293T cells overexpressing human pro-IL-33 contained essentially the 30kD full length form of pro-IL-33, even after incubation with caspase-1, as well as a minor band at 20 kD ( Figure 1C ). Again similar results were obtained using two different anti-hIL-33 antibodies (AF3625 and ALX-804-726, Alexis Corporation) for detection ( Figure  1C and data not shown).
For both mouse and human IL-33, the observed 20 kD fragment was of higher molecular weight than recombinant 18 kD IL-33. This 20 kD band was generally detectable already before caspase-1 treatment, although its abundance was variable in different cell lysate preparations (Figure 1 and data not shown) . However, the full length 30 kD pro-IL-33 remained the most abundant form detected in all preparations, even in presence of caspase-1. Finally, lysates of 293T cells overexpressing pro-IL-1β were used as a positive control for efficient caspase-1 activity in our experimental conditions, and indeed pro-IL-1β was efficiently cleaved into its 17kD mature form ( Figure 1D) .
IL-33 is not a direct substrate for caspase-1. The presence of the 20kD band in untreated cell lysates, as well as in cells transfected with mutant pro-IL-33, suggested that generation of this IL-33 fragment is not mediated directly by caspase-1. In fact, 293T cell lysates contain a number of proteases, which might be involved in IL-33 processing. We thus sought to assay caspase-1 cleavage of pro-IL-33 in a protease-free system. To this end, we synthesized pro-IL-33 using an in vitro transcription/translation system reconstituted from purified and recombinant components, which is essentially protease free. Interestingly, when incubating in vitro synthesized mouse (Figure 2A ) or human ( Figure  2B ) pro-IL-33 with recombinant human active caspase-1, we could not observe any caspase-1 dependent cleavage of pro-IL-33, which was exclusively recovered in its full length 30 kD form, even after 6h of incubation. In contrast, using the same experimental conditions, human pro-IL-1β was totally cleaved to generate 17 kD mature IL-1β ( Figure 2C ). Taken together, these observations demonstrate that, in contrast to pro-IL-1β, pro-IL-33 is not a direct substrate for caspase-1.
IL-33 is released in its precursor form after activation of endogenous caspase-1 in THP-1 cells.
We next investigated the effect of caspase-1 activation on pro-IL-33 processing and secretion in living cells. For these experiments, we used THP-1 cells, because caspase-1 activation and IL-1β secretion have been extensively described in these cells, in response to PMA and LPS, in well-established experimental conditions (16) . In our hands, THP-1 cells did not express endogenous pro-IL-33 as assessed by RT-PCR and Western blotting ( Figure 3B and data not shown). We thus used a lentiviral vector to express human pro-IL-33 in these cells. Figure 3C ).
Pro-IL-33 exerts T1/ST2 dependent biological effects on mast cells.
Since we observed secretion of IL-33 in its pro form, we next investigated whether full-length pro-IL-33, like pro-IL-1α, might be able to activate its cognate cell surface receptor. We thus purified mouse pro-IL-33 from transfected 293T total cell lysates or nuclear extracts using ST2-Fc/protein G beads. Although pro-IL-33 readily bound to these beads, it proved very difficult to elute efficiently using elution conditions compatible with subsequent bioactivity tests, such as elution using a low pH (2.8) buffer ( Figure 4A, left panel) , or, on the contrary, a high pH (11.5) triethanolamine buffer (data not shown). Efficient recovery of pro-IL-33 could only be achieved using stringent denaturing conditions, as illustrated by elution in Laemmli buffer ( Figure 4A, right panel) . In fact, control experiments indicated that pro-IL33 exhibited considerable background binding to protein G beads even in absence of ST2-Fc (data not shown) and this 'stickiness' may thus account for our difficulties to recover bound pro-IL-33. In addition, this observation indicates that binding of pro-IL-33 to ST2-Fc/protein G beads cannot be inferred to demonstrate specific binding of pro-IL-33 to ST2.
Despite this lack of specificity, we used binding of pro-IL-33 to ST2-Fc/protein G beads, followed by acid elution, as a tool to prepare protein fractions enriched in pro-IL-33. Full length 30 kD pro-IL-33 was the only form of IL-33 detectable in ST2Fc/protein G beads eluates ( Figure 4A, right panel) . Addition of eluted fractions to P815 mastocytoma cells induced IL-6 secretion and this effect was prevented in presence of sST2-Fc (data not shown). Consistently, eluted pro-IL-33 induced IL-6 secretion in wild-type BMMC, but not in ST2 knockout BMMC (Figure 4B ), further suggesting that pro-IL-33 exerts T1/ST2 dependent biological effects in mast cells. The responsiveness to LPS was similar in wild-type and ST2 knockout BMMC, indicating that there is no intrinsic defect in the induction of IL-6 secretion by pro-inflammatory stimuli in ST2 knockout cells.
In view of the difficulties encountered with the purification of pro-IL-33 from cell lysates, we used in vitro synthesized proteins as an alternative source of pro-IL-33 to further characterize its biological effects. In vitro synthesized mouse pro-IL33 dose dependently induced IL-6 production in P815 cells and this effect was inhibited in presence of sST2-Fc ( Figure 5A ). The two mutant forms of mouse pro-IL-33, D88A and D106A, similarly induced IL-6 production in P815 cells, and their effect was also inhibited by sST2-Fc ( Figure 5B ). Finally, we investigated potential in situ processing of pro-IL-33 to shorter forms in the culture medium of P815 cells. These cells do not express caspase-1, as assessed by RT-PCR (data not shown), but we hypothesized that, after addition to the cultures, pro-IL-33 might be processed by other secreted or cell surface proteases. Indeed, we could detect processing of pro-IL-33 to shorter forms, in particular 28 kD, 20 kD and 18 kD fragments ( Figure 5C ), although, after 24h incubation with P815 cells, the relative abundance of full-length pro-IL-33 and of these shorter fragments was variable in between experiments ( Figure 5C and data not shown). The presence of shorter forms was also observed when P815 cells were incubated with the D88A and D106A mutant forms of pro-IL-33 (data not shown). It thus remains to be determined which forms of IL-33 indeed correspond to biologically active molecules.
DISCUSSION
In this study, we report generation of a 20 kD fragment of IL-33 in cell lysates, which is enhanced by incubation with caspase-1 in vitro. The molecular weight of this fragment is higher than that of recombinant, so-called mature, IL-33. We further demonstrate that generation of this fragment is not mediated directly by caspase-1, which does not cleave pro-IL-33 in an in vitro system devoid of contaminating proteases. In addition, our results indicate that caspase-1 cleavage is not required for pro-IL-33 secretion and bioactivity. While it is generally assumed that IL-33 processing is regulated similarly to that of IL-1β, our data thus highlight major differences between these two cytokines.
We believe that the 20 kD form of IL-33, which we observed using both the mouse and human proteins, in fact corresponds to the mature form of IL-33 initially described by Schmitz and colleagues after incubation of human pro-IL-33 with caspase-1 (1). In this early work, the molecular weight of this short IL-33 form was indeed not directly compared to that of recombinant IL-33. Our data further suggest that the cleavage reported in this study was not due directly to caspase-1, but rather mediated by contaminating proteases, which are known to be present in reticulocyte lysates (16) . Caspase-1 has indeed been observed previously to directly or indirectly mediate activation of other downstream proteases (4, 18) . In support of this hypothesis, we observed the presence of the 20 kD form of IL-33 to a variable extent already in lysates of 293T cells, which do not express endogenous caspase-1 (DTA, CG, GP, unpublished observations), before addition of recombinant active caspase-1. Furthermore, generation of this fragment was still observed with the D88A and D106A mutant forms of mouse pro-IL-33, indicating that it was independent of the presence of the two potential caspase-1 cleavage sites present in the N-terminal moiety of mouse pro-IL-33. Finally, our observations fit the lack of a conserved region corresponding to a potential caspase-1 cleavage site between species. Interestingly, generation of this 20 kD form of IL-33 was not observed only in vitro, but also in THP-1 cells. The mechanisms underlying its production, as well as its functional relevance remain to be investigated.
Another interesting observation is the release of full-length pro-IL-33 into the supernatants of LPS activated THP-1 cells, suggesting that pro-IL-33 can be secreted in absence of caspase-1 processing. Consistently with our results, the presence of full-length pro-IL-33 in the supernatants of activated THP-1 cells has been detected previously (9) . In this previous report, two shorter forms of IL-33 were also observed in THP-1 supernatants. We cannot formally exclude from our data that shorter forms of IL-33 may also be released into THP-1 supernatants, at concentrations falling below the detection limit of our Western blot analysis. Alternatively, fulllength pro-IL-33 might be further processed within THP-1 culture supernatants by extracellular or cell surface proteases, as it is the case with P815 cells. The selective release of pro-IL-33 by LPS-activated cells suggests that, although pro-IL-33 is not a substrate for caspase-1, its secretion may be dependent upon caspase-1 activation. This observation is consistent with a recent study describing caspase-1 dependent secretion of a number of leaderless proteins, including IL-1α, which are not caspase-1 substrates (19) . In addition to its specific release by activated cells, pro-IL-33 was also recently suggested to function as an alarmin upon leakage from damaged endothelial or epithelial cells, which constitutively express its nuclear pro form (7) .
Finally, incubation with full-length pro-IL-33 induced T1/ST2 dependent biological effects in mast cells. However, since we observed variable extents of processing of wild-type and Asp to Ala mutant pro-IL-33 proteins in P815 culture medium during the time frame used for stimulation, it is not clear at this stage whether the full-length form itself, or/and one or several cleavage products represent the truly bioactive species. Interestingly, in contrast to the various cell lysates we analyzed, P815 culture media also contained a 18kD form of IL-33, which was similar in size to the recombinant protein. In any event, P815 cells do not express caspase-1, indicating that extracellular IL-33 processing is again caspase-1 independent. Taken together, our data clearly demonstrate that, in contrast to IL-1β, IL-33 bioactivity does not require activation by caspase-1 cleavage.
In conclusion, we describe generation of a 20 kD fragment of mouse and human IL-33, which is different from recombinant IL-33. This fragment is not produced by direct caspase-1 cleavage. In fact, our results indicate that pro-IL-33 is not a substrate for this enzyme. We also observed that pro-IL-33 is released in its fulllength form by activated THP-1 cells and that addition of pro-IL-33 induces T1/ST2 dependent biological effects in mast cells. Taken together, our results clearly indicate that caspase-1 cleavage is not required for IL-33 secretion and bioactivity. Figure 4 . Purified pro-IL-33 exerts T1/ST2 dependent biological effects on mast cells. (A) Mouse pro-IL-33 was purified from total cell lysates or nuclear extracts of transfected 293T cells using sST2-Fc/protein G beads, as described in 'Materials and Methods'. Total cell lysate used for purification (load, 10 µl out of 500), column flow through (FT, 10 µl out of 500), first wash (wash, 10 µl out of 500), and eluted fractions 1-4 (el1-el4, 10 µl out of 100) were analyzed by Western blotting using the Nessy anti-IL-33 antibody (left panel). Alternatively, 10 µl of ST2-Fc/protein G beads were incubated with 20 µl of total cell lysate, washed, and pro-IL-33 was eluted directly in Laemmli buffer (lb el, right panel). rmIL-33: recombinant mouse IL-33; lysate: total cell lysate (1.5 µl). (B) Wild-type and T1/ST2 knockout BMMC were stimulated for 24h with 10 µl of purified pro-IL-33, 1 µg/ml LPS or 1 ng/ml rmIL-33 before IL-6 secretion was assessed in culture supernatants by ELISA. Results shown are mean + SEM of culture triplicates. Similar results were obtained with eluates from 3 independent purifications. *p<0.05 vs. control, &p<0.05 vs. wild-type BMMC with same stimulation. 
